Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Burger

Showing results (771-780 of 1,123) with videos related to

Pageof 113
Sort By:
Antiviral Therapy|February 22, 2000
Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapyD M Burger, R M Hoetelmans, P W Hugen, et al.
Clinical and Translational Science|February 14, 2020
Quantification of Adverse Drug Reactions Related to Drug Switches in The NetherlandsPieter J Glerum, Marc Maliepaard, Vincent de Valk, et al.
International Journal of Antimicrobial Agents|December 5, 2022
Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA)H A B Prins, L Zino, E M Svensson, et al.
Antiviral Therapy|February 5, 2008
Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimenReshma S Autar, Mark A Boyd, Ferdinand W M N Wit, et al.
Clinical Pharmacokinetics|April 12, 2014
Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerationsClara T M M de Kanter, Joost P H Drenth, Joop E Arends, et al.
Topics in Antiviral Medicine|February 18, 2014
Ergotism in Thailand caused by increased access to antiretroviral drugs: a global warningAnchalee Avihingsanon, Reshmie A Ramautarsing, Gompol Suwanpimolkul, et al.
European Journal of Gastroenterology & Hepatology|August 24, 2010
Suboptimal endogenous erythropoietin response in chronic hepatitis C patients during ribavirin and PEG interferon treatmentLotte G Van Vlerken, Hanneke Van Soest, Mart P Janssen, et al.
Clinical Pharmacology and Therapeutics|January 2, 2009
A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adultsA Avihingsanon, J van der Lugt, S J Kerr, et al.
Journal of Viral Hepatitis|December 1, 2010
Ribavirin rather than PEG-interferon pharmacodynamics predict nonresponse to antiviral therapy in naive chronic hepatitis C patientsL G van Vlerken, E J Huisman, H van Soest, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 4, 2003
Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjectsMark A Boyd, Rob E Aarnoutse, Kiat Ruxrungtham, et al.
Pageof 113

Showing results (771-780 of 1,123) with videos related to

Sort By:
Pageof 113
Antiviral Therapy|February 22, 2000
Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapyD M Burger, R M Hoetelmans, P W Hugen, et al.
Clinical and Translational Science|February 14, 2020
Quantification of Adverse Drug Reactions Related to Drug Switches in The NetherlandsPieter J Glerum, Marc Maliepaard, Vincent de Valk, et al.
International Journal of Antimicrobial Agents|December 5, 2022
Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA)H A B Prins, L Zino, E M Svensson, et al.
Antiviral Therapy|February 5, 2008
Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimenReshma S Autar, Mark A Boyd, Ferdinand W M N Wit, et al.
Clinical Pharmacokinetics|April 12, 2014
Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerationsClara T M M de Kanter, Joost P H Drenth, Joop E Arends, et al.
Topics in Antiviral Medicine|February 18, 2014
Ergotism in Thailand caused by increased access to antiretroviral drugs: a global warningAnchalee Avihingsanon, Reshmie A Ramautarsing, Gompol Suwanpimolkul, et al.
European Journal of Gastroenterology & Hepatology|August 24, 2010
Suboptimal endogenous erythropoietin response in chronic hepatitis C patients during ribavirin and PEG interferon treatmentLotte G Van Vlerken, Hanneke Van Soest, Mart P Janssen, et al.
Clinical Pharmacology and Therapeutics|January 2, 2009
A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adultsA Avihingsanon, J van der Lugt, S J Kerr, et al.
Journal of Viral Hepatitis|December 1, 2010
Ribavirin rather than PEG-interferon pharmacodynamics predict nonresponse to antiviral therapy in naive chronic hepatitis C patientsL G van Vlerken, E J Huisman, H van Soest, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 4, 2003
Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjectsMark A Boyd, Rob E Aarnoutse, Kiat Ruxrungtham, et al.
Pageof 113